Education
About Us
Working with TipRanks
Follow Us
Invex Therapeutics Ltd. (AU:IXC)
ASX:IXC
RESEARCH TOOLSreports
IXC Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.10
Previous CloseN/A
Volume14.00K
Average Volume (3M)28.42K
Market Cap
AU$6.76M
Enterprise ValueAU$957.39K
Total Cash (Recent Filing)AU$5.81M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)60.0
Beta0.83
Next Earnings
Aug 22, 2025EPS EstimateN/A
Last Dividend Ex-Date
Dec 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding75,153,850
10 Day Avg. Volume1,493
30 Day Avg. Volume28,416
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)1.27
Price to Sales (P/S)0.00
P/FCF Ratio-18.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Invex Therapeutics Ltd. News
PremiumCompany Announcements
Invex Therapeutics Updates Registered Office Address
PremiumCompany Announcements
Invex Therapeutics Reports Reduced Losses but Withholds Dividends
PremiumCompany Announcements
Invex Therapeutics Secures £114k R&D Tax Rebate from UK Government
PremiumCompany Announcements
Invex Therapeutics Unveils Promising Alzheimer’s Treatment Results
PremiumCompany Announcements
Invex Therapeutics Announces AGM Results and Future Focus
PremiumCompany Announcements
Invex Therapeutics Restructures Amid Clinical Trial ChallengesIXC FAQ
What was Invex Therapeutics Ltd.’s price range in the past 12 months?
Invex Therapeutics Ltd. lowest share price was AU$0.05 and its highest was AU$0.10 in the past 12 months.
What is Invex Therapeutics Ltd.’s market cap?
Invex Therapeutics Ltd.’s market cap is AU$6.76M.
When is Invex Therapeutics Ltd.’s upcoming earnings report date?
Invex Therapeutics Ltd.’s upcoming earnings report date is Aug 22, 2025 which is in 34 days.
How were Invex Therapeutics Ltd.’s earnings last quarter?
Currently, no data Available
Is Invex Therapeutics Ltd. overvalued?
According to Wall Street analysts Invex Therapeutics Ltd.’s price is currently Overvalued.
Does Invex Therapeutics Ltd. pay dividends?
Invex Therapeutics Ltd. pays a Notavailable dividend of AU$0.186 which represents an annual dividend yield of N/A. See more information on Invex Therapeutics Ltd. dividends here
What is Invex Therapeutics Ltd.’s EPS estimate?
Invex Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invex Therapeutics Ltd. have?
Invex Therapeutics Ltd. has 75,153,850 shares outstanding.
What happened to Invex Therapeutics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Invex Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:IXC
Invex Therapeutics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.00%
12-Months-Change
Fundamentals
Return on Equity
2.14%
Trailing 12-Months
Asset Growth
-6.63%
Trailing 12-Months
Company Description
Invex Therapeutics Ltd.
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.
Technical Analysis
Alterity Therapeutics
―
AnteoTech Ltd
―
AdAlta Ltd.
―
Chimeric Therapeutics Ltd.
―
Recce Pharmaceuticals Ltd.
―